Absci is trading at $10.49, up 11.03%, amid a biotech rally; no clear company-specific catalyst has been identified.
- XBI is reported up 2.18%, amid positive clinical-trial and regulatory news across the sector.
- Absci announced participation in three upcoming investor conferences, but that announcement does not explain the move.
- Broader markets are also higher, though available evidence does not establish a direct cause for Absci’s larger gain.